Phase I and pharmacokinetic study of trabectedin in Japanese patients with soft tissue sarcoma

被引：0
|
作者：
Yonemori, K. [1 ]
Ueda, T. [2 ]
Sugiura, H. [3 ]
Kawai, A. [4 ]
Ando, M.
机构：
[1] Natl Canc Ctr, Breast & Med Oncol Div, Tokyo 104, Japan
[2] Osaka Natl Hosp, Dept Orthoped Surg, Osaka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3838
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [1] Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
    Sessa, C.
    Perotti, A.
    Noberasco, C.
    De Braud, F.
    Gallerani, E.
    Cresta, S.
    Zucchetti, M.
    Vigano, L.
    Locatelli, A.
    Jimeno, J.
    Feilchenfeldt, J. W.
    D'Incalci, M.
    Capri, G.
    Ielmini, N.
    Gianni, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (07) : 1153 - 1161
  • [2] Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
    Blay, Jean-Yves
    von Mehren, Margaret
    Samuels, Brian L.
    Fanucchi, Michael P.
    Ray-Coquard, Isabelle
    Buckley, Brigid
    Gilles, Leen
    Lebedinsk, Claudia
    Elsayed, Yusri A.
    Le Cesne, Axel
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6656 - 6662
  • [3] Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
    Takafumi Ueda
    Shigeki Kakunaga
    Masashi Ando
    Kan Yonemori
    Hideshi Sugiura
    Kenji Yamada
    Akira Kawai
    [J]. Investigational New Drugs, 2014, 32 : 691 - 699
  • [4] Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
    Ueda, Takafumi
    Kakunaga, Shigeki
    Ando, Masashi
    Yonemori, Kan
    Sugiura, Hideshi
    Yamada, Kenji
    Kawai, Akira
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 691 - 699
  • [5] Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma
    Cioffi, Angela
    Italiano, Antoine
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (01) : 113 - 122
  • [6] A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma
    Buonadonna, Angela
    Benson, Charlotte
    Casanova, Jose
    Kasper, Bernd
    Lopez Pousa, Antonio
    Mazzeo, Filomena
    Brodowicz, Thomas
    Penel, Nicolas
    [J]. ANTI-CANCER DRUGS, 2017, 28 (10) : 1157 - 1165
  • [7] Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
    Corona, Giuseppe
    Di Gregorio, Emanuela
    Buonadonna, Angela
    Lombardi, Davide
    Scalone, Simona
    Steffan, Agostino
    Miolo, Gianmaria
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [8] Trabectedin (Yondelis®) in Soft Tissue Sarcoma
    Zintl, Patrik
    Santabarbara, Pedro
    [J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 29 - 31
  • [9] The Role of Trabectedin in Soft Tissue Sarcoma
    Nakamura, Tomoki
    Sudo, Akihiro
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
    Angarita, Fernando A.
    Cannell, Amanda J.
    Razak, Albiruni R. Abdul
    Dickson, Brendan C.
    Blackstein, Martin E.
    [J]. BMC CANCER, 2016, 16
12345